No abstract available
MeSH terms
-
Administration, Oral
-
Aged
-
Anticoagulants / adverse effects
-
Anticoagulants / pharmacokinetics
-
Anticoagulants / therapeutic use*
-
Antidotes / therapeutic use
-
Atrial Fibrillation / blood
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy
-
Dabigatran / adverse effects
-
Dabigatran / pharmacokinetics
-
Dabigatran / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Female
-
Hemorrhage / chemically induced
-
Hemorrhage / drug therapy
-
Humans
-
Metabolic Clearance Rate / physiology
-
Pregnancy
-
Pyrazoles / adverse effects
-
Pyrazoles / pharmacokinetics
-
Pyrazoles / therapeutic use
-
Pyridines / adverse effects
-
Pyridines / pharmacokinetics
-
Pyridines / therapeutic use
-
Pyridones / adverse effects
-
Pyridones / pharmacokinetics
-
Pyridones / therapeutic use
-
Rivaroxaban / adverse effects
-
Rivaroxaban / pharmacokinetics
-
Rivaroxaban / therapeutic use
-
Stroke / blood
-
Stroke / prevention & control*
-
Thiazoles / adverse effects
-
Thiazoles / pharmacokinetics
-
Thiazoles / therapeutic use
-
Thromboembolism / blood
-
Thromboembolism / prevention & control*
Substances
-
Anticoagulants
-
Antidotes
-
Pyrazoles
-
Pyridines
-
Pyridones
-
Thiazoles
-
apixaban
-
Rivaroxaban
-
Dabigatran
-
edoxaban